Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Tremfya achieved an impressions share of voice (SOV) of 3.35%, generating 2.1 billion total impressions. While the brand held the top spot, the total impressions dipped by 2 million from when Sanofi ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading ...

A study found that children with early-onset atopic dermatitis have a higher risk of developing uveitis and should be closely ...

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...